New FY 2024 plans would retain only 74% of staff, compared to the original, which retained 81%, but still increase the number of workers retained because of user fees.
Updated plans indicate the US Food and Drug Administration would furlough substantially more employees than thought at the beginning of fiscal year 2024, potentially adding to the stress on services should the government shut down.
Federal agency budgets have been running on a continuing resolution since FY 2024 began on 1 October 2023. FDA funding...
Recent studies show that spaceflight can significantly weaken astronauts’ immune systems, making them more susceptible to infections and health complications during and after missions. Understanding these changes is crucial for ensuring the safety of future long-duration space travelers.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
